Source disclosure: February 06, 2026
Eisai Co., Ltd. [4523.T]
TOKYO, Feb 06 (Pulse News Wire) – Eisai CO.,LTD. (4523.T) reported global sales revenue for its anti-Amyloid beta protofibril antibody drug Leqembi® (generic name: lecanemab) exceeded expectations during the fiscal quarter ending December 31, 2025.
Preliminary figures show total sales reached ¥61.80 billion. Sales performance varied across key markets, with the United States contributing ¥31.20 billion, Japan reporting ¥17.90 billion, and China accounting for ¥8.300 billion.
Eisai disclosed these preliminary results in conjunction with Biogen Inc.'s (Cambridge, MA) earnings release on April 01, 2025. Further details on Leqembi's sales and Eisai’s overall Q3 financial performance will be released during the company's scheduled earnings presentation on February 09, 2026.
Eisai leads development and regulatory filings globally for Leqembi, while commercialization and promotional activities are conducted jointly with Biogen under Eisai's final decision-making authority.
AI-translated content. 🟢 Confidence: High See terms • Original filing